Quarterly report pursuant to Section 13 or 15(d)

COMMITMENTS AND CONTINGENCIES (Details Narrative)

v3.24.2.u1
COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)
1 Months Ended 6 Months Ended
Jan. 05, 2024
Oct. 04, 2023
Feb. 02, 2023
Jan. 11, 2022
Apr. 24, 2024
May 30, 2019
Jun. 30, 2024
Dec. 31, 2023
Sep. 30, 2019
Dec. 10, 2015
First payment owed       $ 145,000     $ 0      
Accrued Interest             57,412      
Recognized loss on contingency             (322,503)      
Consultant remuneration per month             3,500      
Costs and attorneys' fees             $ 332,503      
Compensation for services, description             As of May 14, 2021, the Company has entered into four consulting agreements. In compensation for services: (i) one consultant shall receive a renumeration amount of $10,000-$12,500 per month and has earned 1% of the Company’s majority owned subsidiary, BioCorRx Pharmaceuticals as of May 7, 2021 based on FDA clearance of Company’s IND application; consulting agreement terminated in April 2021 (ii) one consultant shall receive common stock equivalent to $1,375 on the last day of each month; (iii) two consultants shall receive common stock equivalent to $3,750 on the last day of each month; and (iv) one consultant shall receive a remuneration amount of $3,500 per month      
Charles River Laboratories, Inc. [Member]                    
Remaining commitment             $ 28,936      
Payment of amended consideration           $ 3,024,476        
BICX Holding Company LLC [Member]                    
Common stock issued upon convertible debt             2,227,575      
Convertible Promissory Note                 $ 4,160,000  
Conversion agreement description             Pursuant to the Conversion Agreement, BICX has agreed that the Total Interest Payment (as defined in the Conversion Agreement) that would have been due under the Note, in the amount of $1,138,157, will be reflected on the Company’s financial statements as an amount due and owing to the Investor to be repaid within twelve (12) months of the closing of the Public Offering, or if the Public Offering is terminated or abandoned prior to closing, then on or before such date that is no later than twelve (12) months from the date of such termination or abandonment. As of June 30, 2024, the Public Offering has not yet been abandoned by the Company      
Issuance price             $ 2.00      
Orange County Research Center [Member]                    
Consideration amount       $ 657,640     $ 503,089      
Pellecome [Member]                    
Attorney's fees             $ 235,886      
Attorney's fees received or awarded   $ 222,933 $ 222,933              
Interest rate             10.00%      
Pellecome [Member] | January 5, 2024 [Member]                    
Attorney's fees received or awarded             $ 332,503      
Consultant [Member]                    
Renumeration amount             $ 1,417      
Issue of common stock to consultant             3,000      
Alpine Creek [Member]                    
Royalty due             $ 91 $ 91    
Total consideration amount             1,531,926 $ 1,531,926    
Payables to Alpine Creek                   $ 1,215,000
Paid to Alpine Creek             $ 1,620,000      
Payable commitment description             On any other proprietary implant distribution, that excludes the “treatment”, for alcohol and opioid addiction and for which no other payment is due, the Company shall pay 2.5% of the Company’s gross profit for implant distribution not to exceed $100 per sale. On or about January 1, 2021, Mr. Galligan acquired from Alpine Creek the rights to the royalty agreement by and between the Company and Alpine Creek. As of June 30, 2024 and December 31, 2023, there are no payments due      
Payable per treatment sold                   $ 100
Profit holding percentage                   50.00%
Mr Lucido [Member]                    
Accrued Interest         $ 7,858          
Mr Lucido [Member] | January 5 2024 [Member]                    
Annual compensation $ 200,000